Core Viewpoint - Raymond James raised its price target on Cogent Biosciences Inc. to $60 from $30, reiterating a Strong Buy rating following a significant data release in GIST treatment, leading to a 119% surge in Cogent shares [1] Group 1: Clinical Trial Results - The PEAK clinical trial demonstrated a 7.3-month progression-free survival advantage for Cogent's treatment compared to standard sunitinib monotherapy in second-line GIST, marking a notable efficacy gain in the field [1] Group 2: Revenue Projections - The results from the clinical trial opened a $4 billion incremental revenue opportunity for Cogent, with revised GIST revenue projections of $194 million for fiscal 2027, $445 million for 2028, $759 million for 2029, and $1.03 billion for 2030 [2] - These revisions contributed approximately $25 per share to Cogent's discounted cash flow and sum-of-parts valuation [2] Group 3: Future Expectations - Strong expectations are set for Cogent's systemic mastocytosis therapy, with a New Drug Application anticipated by the end of 2025 and potential approval and launch between Q2 and Q3 of 2026 [3] - Cogent is reaffirmed as the top pick among small-cap biotech names by Raymond James [3]

Core Viewpoint - The ongoing antitrust trial against Meta Platforms could lead to the forced divestiture of its segments like Instagram and WhatsApp, potentially unlocking shareholder value through a sum-of-parts valuation [1][2][3]. Financial Implications - The trial is set against the backdrop of Meta's first-quarter financial results, which are expected to show weak guidance [2][7]. - The current market cap of Meta is $1.27 trillion, with survey results indicating that 50% of respondents believe a breakup could yield a higher valuation than the current market cap [9]. Survey Insights - A Benzinga survey revealed that half of the respondents think Meta's stock could be worth more if a forced spinoff or breakup occurs [5]. - Instagram is viewed as the most valuable asset in the event of a breakup, with 43% of respondents expressing interest in owning it [10]. Historical Context - Meta acquired Instagram for $1 billion in 2012, a decision that was initially met with skepticism due to Instagram's limited revenue at the time [7]. - Since the acquisition, Instagram has grown to approximately two billion users, becoming a significant growth driver for Meta [8]. Competitive Landscape - Meta has defended itself against antitrust allegations by highlighting competition from platforms like TikTok and YouTube [9].